<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04008004</url>
  </required_header>
  <id_info>
    <org_study_id>EDP 514-001</org_study_id>
    <nct_id>NCT04008004</nct_id>
  </id_info>
  <brief_title>A Study of EDP-514 in Healthy Subjects (Part 1) and Patients With Chronic Hepatitis B Virus Infection (Part 2)</brief_title>
  <official_title>A Phase 1a/1b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of EDP 514 in Healthy Subjects (Part 1), and Antiviral Activity in Nucleos(t)Ide Reverse Transcriptase Inhibitor (NUC)-Suppressed Patients With Chronic Hepatitis B Virus Infection (Part 2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Enanta Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pharmaceutical Research Associates</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Enanta Pharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Part 1 is a randomized, double-blind, placebo-controlled study. It will assess the safety,
      tolerability, and pharmacokinetics of single and multiple orally administered doses of
      EDP-514 in healthy adult subjects.

      Part 2 is randomized, double -blind, placebo-controlled study including subjects with
      Hepatitis B Virus. It will assess the safety, tolerability, pharmacokinetics and antiviral
      activity of 28 Days of orally administered doses of EDP-514 in nucleos(t)ide reverse
      transcriptase inhibitor (NUC)-Suppressed Patients with Chronic Hepatitis B Virus Infection
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1 consists of two phases planned in healthy subjects:

      The first phase assesses single ascending doses for EDP-514 (active drug or placebo) in
      healthy subjects. A &quot;fasted&quot; and &quot;fed&quot; two-part cohort will also assess food effect.

      The second phase assesses multiple ascending doses (active drug or placebo) for 14 days in
      healthy subjects.

      Each cohort within each phase will enroll a total of 8 subjects who will be randomized to
      receive EDP-514 or placebo. The cohort assessing food effect will enroll 10 subjects
      randomized to receive EDP-514 or placebo.

      Part 2 assesses multiple ascending doses EDP-514 (active drug or placebo) for 28 days in
      nucleos(t)ide reverse transcriptase inhibitor (NUC)-Suppressed Patients with Chronic
      Hepatitis B Virus Infection.

      Each cohort in Part 2 will enroll a total of 8 subjects who will be randomized to receive
      EDP-514 or placebo.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 26, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety measured by adverse events</measure>
    <time_frame>Up to 8 Days in HV SAD Cohorts</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety measured by adverse events</measure>
    <time_frame>Up to 21 Days in HV MAD Cohorts</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety measured by adverse events</measure>
    <time_frame>Up to 56 Days in HBV MAD Cohorts</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax of EDP-514</measure>
    <time_frame>Up to 6 Days in HV SAD Cohorts</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of EDP-514</measure>
    <time_frame>Up to 6 Days in HV SAD Cohorts</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of EDP-514</measure>
    <time_frame>Up to 18 Days in HV MAD Cohorts</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of EDP-514</measure>
    <time_frame>Up to 18 Days in HV MAD Cohorts</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of EDP-514</measure>
    <time_frame>Up to 28 Days in HBV MAD Cohorts</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of EDP-514</measure>
    <time_frame>Up to 28 Days in HBV MAD Cohorts</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">98</enrollment>
  <condition>Chronic HBV Infection</condition>
  <arm_group>
    <arm_group_label>EDP-514 HV SAD Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EDP-514 Dose 1, Dose 2, Dose 3, Dose 4, Dose 5 and Dose 6 orally, once daily in one single administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EDP-514 HV MAD Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EDP-514 Dose 1, Dose 2 and Dose 3 orally, once daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EDP-514 HV SAD Placebo Cohort</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo, orally, once daily in one single administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EDP-514 HV MAD Placebo Cohort</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo, orally, once daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EDP-514 HBV MAD Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EDP-514 Dose 1, Dose 2 and Dose 3 orally, once daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EDP-514 HBV MAD Placebo Cohort</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo, orally, once daily for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EDP-514</intervention_name>
    <description>Oral Capsule; Subjects will receive either a single dose of EDP-514 on Day 1 only (SAD HV), once daily dosing of EDP-514 starting on Day 1 through Day 14 (MAD HV) or once daily dosing of EDP-514 starting on Day 1 through Day 28 (MAD HBV).</description>
    <arm_group_label>EDP-514 HBV MAD Cohorts</arm_group_label>
    <arm_group_label>EDP-514 HV MAD Cohorts</arm_group_label>
    <arm_group_label>EDP-514 HV SAD Cohorts</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to match EDP-514</description>
    <arm_group_label>EDP-514 HBV MAD Placebo Cohort</arm_group_label>
    <arm_group_label>EDP-514 HV MAD Placebo Cohort</arm_group_label>
    <arm_group_label>EDP-514 HV SAD Placebo Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Part 1 (HV Population):

        Inclusion Criteria:

          -  An informed consent document signed and dated by the subject.

          -  Healthy male and female subjects of any ethnic origin between the ages of 18 and 65
             years, inclusive.

        Exclusion Criteria:

          -  Clinically relevant evidence or history of illness or disease.

          -  Pregnant or nursing females.

          -  History of febrile illness within 7 days prior to the first dose of study drug or
             subjects with evidence of active infection.

          -  A positive urine drug screen at screening or Day -1.

          -  Current tobacco smokers or use of tobacco within 3 months prior to screening.

          -  Any condition possibly affecting drug absorption (e.g., gastrectomy, cholecystectomy).

          -  History of regular alcohol consumption.

          -  Receipt of any vaccine, an investigational agent or biological product within 28 days
             or 5 times the t½, whichever one is longer, prior to first dose. This includes agents
             administered during clinical trial participation.

        Part 2 (HBV Population):

        Inclusion Criteria:

          -  An informed consent document signed and dated by the subject.

          -  Healthy male and female subjects of any ethnic origin between the ages of 18 and 70
             years, inclusive

          -  HBV DNA levels:

               -  A Screening HBV DNA level in serum/plasma that is &lt;LLOQ and

               -  No HBV DNA serum/plasma test values ≥LLOQ over the previous 12 months (using an
                  approved test)

          -  CHB subjects must have been on their prescribed HBV NUC treatment with no change in
             regimen for 12 months prior to Screening

        Exclusion Criteria:

          -  A documented prior diagnosis of cirrhosis

          -  Pregnant or nursing females

          -  Coinfection with human immunodeficiency virus (HIV), HCV, HDV, HAV, or HEV

          -  Chronic liver disease of a non-HBV etiology; coexisting liver or biliary diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enanta Pharmaceuticals, Inc</last_name>
    <role>Study Director</role>
    <affiliation>Enanta Pharmaceuticals, Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Enanta Pharmaceuticals, Inc</last_name>
    <phone>+1 617 607 0705</phone>
    <email>nadda@enanta.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Southern California GI and Liver Centers</name>
      <address>
        <city>Coronado</city>
        <state>California</state>
        <zip>92118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tarek Hassanein</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tuan Nguyen Md Gastroenterology &amp; Hepatology (Tuan Nguyen, M.D., Inc.)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Quest Clinical Research</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pharmaceutical Research Associates, Inc.</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>American Research Corporation</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Galati</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Texas Liver Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Lawitz, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>July 2, 2019</study_first_submitted>
  <study_first_submitted_qc>July 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2019</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>&quot;First-in-Human&quot;</keyword>
  <keyword>Single Ascending Dose</keyword>
  <keyword>Multiple Ascending Dose</keyword>
  <keyword>hepatitis B virus</keyword>
  <keyword>HBV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Herpesviridae Infections</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

